Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Stannous protoporphyrin - Renibus Therapeutics

Next Previous
Drug Profile

Stannous protoporphyrin - Renibus Therapeutics

Alternative Names: RBT-9; SnPP; Tin-protoporphyrin IX - Renibus Therapeutics

Latest Information Update: 15 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Renibus Therapeutics
  • Class Anti-inflammatories; Antianaemics; Antivirals; Cytoprotectives; Heavy metals; Metalloporphyrins
  • Mechanism of Action Antioxidants; Decyclizing heme oxygenase inhibitors; Immunomodulators; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • Preclinical Non-alcoholic steatohepatitis
  • No development reported Acute kidney injury

Most Recent Events

  • 13 Dec 2022 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Acute kidney injury(Prevention) in USA
  • 17 Feb 2022 Renibus Therapeutics terminates the phase II PREVENT trial in COVID-2019 infections in USA due to enrolment feasibility (IV) (NCT04364763)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top